{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-333813","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-08-05T11:02:49+00:00","discovered_at":"2026-08-05T11:05:00.318095+00:00","generated_at":"2026-08-05T11:06:17.955031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Q32 Bio Q2 net loss $8.9M; positive bempikibart Phase 2a data; $200M offering","bullets":["Net loss $8.9M ($0.44/share) vs $9.5M ($0.78) in Q2 2025; R&D expense $4.3M, G&A $4.9M.","Cash $106.3M at June 30, 2026; combined with $200M July offering funds through Phase 3 topline.","Bempikibart showed 35.3% mean SALT reduction at Week 36; 40% SALT-20 response (mITT) in SIGNAL-AA Part B.","Registration-directed program for severe/very severe AA expected to start 1H2027, pending regulatory discussions.","ADX-914-XL (half-life extended anti-IL-7Rα) advancing in preclinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-333813","json":"https://secwatch.observer/filing/0001193125-26-333813.json","markdown":"https://secwatch.observer/filing/0001193125-26-333813.md","text":"https://secwatch.observer/filing/0001193125-26-333813.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/0001193125-26-333813-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/qttb-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:06:17.955031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}